BriaCell Therapeutics Corp.
BCTX
$4.50
$0.194.41%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.56M | 6.55M | 6.39M | 6.31M | 6.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.74M | 30.37M | 27.20M | 24.42M | 27.32M |
| Operating Income | -30.74M | -30.37M | -27.20M | -24.42M | -27.32M |
| Income Before Tax | -29.96M | -29.01M | -26.56M | -19.64M | -11.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.96 | -29.01 | -26.56 | -19.64 | -11.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 326.60K | 297.90K | 244.20K | 206.10K | 131.60K |
| Net Income | -29.64M | -28.71M | -26.31M | -19.43M | -11.59M |
| EBIT | -30.74M | -30.37M | -27.20M | -24.42M | -27.32M |
| EBITDA | -30.63M | -30.27M | -27.10M | -24.27M | -27.19M |
| EPS Basic | -32.56 | -53.28 | -81.60 | -82.57 | -50.06 |
| Normalized Basic EPS | -20.26 | -33.16 | -50.79 | -51.27 | -30.97 |
| EPS Diluted | -32.57 | -53.30 | -81.62 | -82.57 | -50.07 |
| Normalized Diluted EPS | -20.26 | -33.16 | -50.79 | -51.27 | -30.97 |
| Average Basic Shares Outstanding | 5.94M | 3.40M | 1.70M | 940.40K | 673.30K |
| Average Diluted Shares Outstanding | 5.94M | 3.40M | 1.70M | 940.40K | 673.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |